This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients

  • identifier


  • Recruitment Status


  • First Posted

    May 3, 2019

  • Last update posted

    February 16, 2021

Study Description

Brief summary:

This is a prospective cohort study aimed to evaluate change of cardiovascular calcification after parathyroidectomy in patients with end-stage renal disease on dialysis compared with control group on conservative treatment.

  • Condition or Disease:Dialysis
    Secondary Hyperparathyroidism
    Chronic Kidney Disease Mineral and Bone Disorder
    Vascular Calcification
  • Intervention/Treatment:
  • Phase: N/A

Detailed Description


Study Design

  • Study Type: Observational
  • Estimated Enrollment: 60 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: December 2022
  • Estimated Study Completion Date: December 2022

Outcome Measures

  • Primary Outcome Measures: 1. Change in coronary artery calcium score measured with CT [ Time Frame: 18 months ]
  • 2. Change in vascular calcification score measured with semi-quantitative (Kauppila) test [ Time Frame: 18 months ]
  • Secondary Outcome Measures: 1. Change in heart valve calcium score [ Time Frame: 18 months ]
  • 2. Change in intact parathyroid hormone (iPTH) level [ Time Frame: 18 months ]
  • 3. Change in serum calcium level [ Time Frame: 18 months ]
  • 4. Change in serum phosphate level [ Time Frame: 18weeks ]
  • 5. Change in alkaline phosphatase [ Time Frame: 18 months ]
  • 6. Serious adverse events (cardiovascular events, death, fractures, emergency hospital admissions) during the follow-up period [ Time Frame: 18 months ]

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients receiving long-term dialysis treatment, met the criteria for parathyroidectomy due to severe SHPT


Inclusion Criteria:

1. Age > 18 years

2. ESRD patients receiving long-term hemodialysis or peritoneal dialysis treatment

3. Severe secondary hyperparathyroidism defined as iPTH level > 800 pg/ml, followed with
hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or
diffuse parathyroid hyperplasia confirmed with CT

Exclusion Criteria:

1. Primary hyperparathyroidosis as a cause of ESRD

Contacts and Locations


Contact: Ekaterina Parshina, MD +7(812)676-25-25


Russian Federation
Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov
Saint Petersburg

Sponsors and Collaborators

Saint Petersburg State University, Russia


Principal Investigator: Ekaterina Parshina, MD Saint Petersburg State University, Russia

More Information

  • Responsible Party: Saint Petersburg State University, Russia
  • Identifier: NCT03937349 History of Changes
  • Other Study ID Numbers: Calcification
  • First Posted: May 3, 2019 Key Record Dates
  • Last Update Posted: February 16, 2021
  • Last Verified: February 2021
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Renal Insufficiency, Chronic
    Hyperparathyroidism, Secondary
    Vascular Calcification
    Bone Diseases
    Kidney Diseases
    Chronic Kidney Disease-Mineral and Bone Disorder